From SARS to avian influenza preparedness in Hong Kong

Clinical Infectious Diseases

Volumn 64, Issue , 2017, Pages S98-S104

  Wong, Andrew T Y ^a   Chen, Hong ^a   Liu, Shao Haei ^b   Hsu, Enoch K ^a   Luk, Kristine S ^c   Lai, Christopher K C ^d   Chan, Regina F Y ^e   Tsang, Owen T Y ^f   Choi, K W ^g   Kwan, Y W ^f   Tong, Anna Y H ^a   Cheng, Vincent C C ^h   Tsang, Dominic N C ⁱ  

^a HOSPITAL AUTHORITY   (Hong Kong)

^b Emergency and Contingency   (Singapore)

^c Princess Margaret Hospital   (Singapore)

^d Queen Elizabeth Hospital   (United Kingdom)

^e United Christian Hospital   (United Kingdom)

^f PRINCESS MARGARET HOSPITAL   (Hong Kong)

^g ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^h Queen Mary Hospital   (India)

ⁱ Hospital Authority Head Office   (United States)

Author keywords

Avian influenza; Emerging infectious diseases; Preparedness

Indexed keywords

AGED; ARTICLE; AVIAN INFLUENZA; CASE REPORT; CLINICAL ARTICLE; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HONG KONG; HUMAN; INFORMATION TECHNOLOGY; LABORATORY TEST; MALE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME; ANIMAL; BIRD DISEASE; CHICKEN; COMMUNICABLE DISEASE; EPIDEMIC; INFLUENZA; INFLUENZA A VIRUS (H5N1); ISOLATION AND PURIFICATION; LEGISLATION AND JURISPRUDENCE; PANDEMIC; PUBLIC HOSPITAL; VIROLOGY;

ANIMALS; CHICKENS; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; HONG KONG; HOSPITALS, PUBLIC; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; PANDEMICS; POULTRY DISEASES; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 85033469479     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix123     Document Type: Article

References (30)

1. Hung LS. The SARS epidemic in Hong Kong: what lessons have we learned? J R Soc Med 2003; 96:374-8
2. SARS Expert Committee, the Government of the Hong Kong Special Administrative Region. SARS in Hong Kong: from experience to action : a summary report of the SARS Expert Committee. 2003. Available at: http://www.sars-expertcom.gov.hk/ english/reports/summary/reports-sumrpt.html. Accessed 9 September 2016
3. The Government of the Hong Kong Special Administrative Region. Preparedness Plan for Influenza Pandemic. 2014. Available at: http://www.chp.gov.hk/files/pdf/ erib-preparedness-plan-for-influenza-pandemic-2014-eng.pdf. Accessed 11 September 2016
4. Working group for reviewing contingency plans for AI &SARS. Review on HA's Preparedness for Influenza Pandemic. 2012. Available at: http://www.ha.org.hk/ haho/ho/cad-bnc/HAB-P175.pdf. Accessed 11 September 2016
5. Leung Y-H, To M-K, Lam T-S, Yau S-W, Leung O-S, Chuang S-K. Epidemiology of human influenza A(H7N9) infection in Hong Kong. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi. doi:10.1016/j.jmii.2015.06.004
6. Liu B, Havers F, Chen E, et al. Risk factors for influenza A(H7N9) disease-China, 2013. Clin Infect Dis 2014; 59:787-94
7. Cheung NT, Fung KW, Wong KC, et al. Medical informatics\-The state of the art in the hospital authority. Int J Med Inform 2001; 62:113-9
8. Cheng VC, Chan JF, To KK, Yuen KY. Clinical management and infection control of SARS: lessons learned. Antiviral Res 2013; 100:407-19
9. Centers for Disease Control and Prevention. Interim guidance for infection control within healthcare settings when caring for confirmed cases, probable cases, and cases under investigation for infection with novel influenza A viruses associated with severe disease. 2016. Available at: http://www.cdc.gov/flu/avianflu/ novel-flu-infection-control.htm. Accessed 21 September 2016
10. World Health Organization. Infection prevention and control of epidemic-and pandemic-prone acute respiratory infections in health care. Geneva: WHO, 2014. Available at: http://apps.who.int/iris/handle/10665/112656. Accessed 21 September 2016
11. Cheng VC, Tai JW, Lee WM, et al. Infection control preparedness for human infection with influenza A H7N9 in Hong Kong. Infect Control Hosp Epidemiol 2015; 36:87-92
12. Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363:617-9
13. Butt KM, Smith GJD, Chen H, et al. Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol 2005; 43:5760-7
14. Cheng VC, Chan JF, Wen X, et al. Infection of immunocompromised patients by avian H9N2 influenza A virus. J Infect 2011; 62:394-9
15. World Health Organization. Avian influenza. 2014. Available at: http://www.who. int/mediacentre/factsheets/avian-influenza/en/. Accessed 9 September 2016
16. Centers for Disease Control and Prevention. Interim guidance on the use of antiviral medications for treatment of human infections with novel influenza A viruses associated with severe human disease. 2016. Available at: http://www.cdc.gov/flu/ avianflu/novel-av-treatment-guidance.htm. Accessed 2 September 2016
17. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a global patient registry. J Infect Dis 2010; 202:1154-60
18. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A. H5N1 Virus. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261-73
19. Liem NT, Tung CV, Hien ND, et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis 2009; 48:1639-46
20. Uyeki TM. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis 2009; 49:279-90
21. Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 2012; 206:1359-66
22. Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 2008; 372:744-9
23. Centers for Disease Control and Prevention. Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses associated with severe human disease and on the use of antiviral medications for chemoprophylaxis. 2016. Available at: http://www.cdc.gov/flu/avianflu/novel-av-chemoprophylaxis-guidance.htm. Accessed 2 September 2016
24. World Health Organization. Avian influenza A (H7N9) virus: Post-exposure antiviral chemoprophylaxis of close contacts of a patient with confirmed H7N9 virus infection and/or high risk poultry/environmental exposures. 2014. Available at: http://www.who.int/influenza/human-animal-interface/influenza-h7n9/13- January-2013-PEP-recs.pdf. Accessed 13 September 2016
25. World Health Organization. Pandemic influenza preparedness and response: a WHO guidance document. Geneva: WHO; 2009
26. Siddiqui MR, Edmunds WJ. Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg Infect Dis 2008; 14:267-74
27. Lugnér AK, Postma MJ. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs. Eur J Public Health 2009; 19:516-20
28. Scientific Committee on Emerging and Zoonotic Diseases, Centre for Health Protection, the Government of the Hong Kong Special Administrative Region. Summary of recommendations on antiviral stockpiling for influenza pandemics. 2014. Available at: http://www.chp.gov.hk/files/pdf/summary-of-recommendations- on-antiviral-stockpiling-for-influenza-pandemics.pdf
29. Government of the Hong Kong Special Administrative Region. Legistlative Council question 3: nursing manpower in public hospitals. Available at: http:// www.info.gov.hk/gia/general/201605/18/P201605180556.htm. Accessed 29 September 2016
30. Government of the Hong Kong Special Administrative Region. Key statistics on service demand of A and E Departments and occupancy rates of medical wards in public hospitals. 2016. Available at: http://www.info.gov.hk/gia/general/ 201603/22/P201603220310.htm. Accessed 15 September 2016